Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 18/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 15/20 | 0.48 |
| ▸ | ATR | Q13535 | 15/20 | 0.47 |
| ▸ | ATRIP | Q8WXE1 | 15/20 | 0.47 |
| ▸ | ATM | Q13315 | 9/20 | 0.46 |
| ▸ | MTOR | P42345 | 6/20 | 0.45 |
| ▸ | SERPINA2 | P20848 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL796977 | 1.00 | PRKDC (0.48) | PRKDCPIK3CBATRATRIPATM | |
| SCHEMBL15131813 | 0.89 | PRKDC (0.54) | PRKDCPIK3CBATRATRIPATM | |
| SCHEMBL15131819 | 0.85 | PRKDC (0.55) | PRKDCPIK3CBATRATRIPATM | |
| SCHEMBL15131817 | 0.81 | PRKDC (0.45) | PRKDCPIK3CBATRATRIPATM | |
| SCHEMBL15131816 | 0.81 | PRKDC (0.45) | PRKDCPIK3CBATRATRIPATM | |
| SCHEMBL797021 | 0.79 | PRKDC (0.46) | PRKDCPIK3CBATRATRIPATM | |
| SCHEMBL797022 | 0.79 | PRKDC (0.46) | PRKDCPIK3CBATRATRIPATM | |
| SCHEMBL15133613 | 0.78 | PIK3CA (0.47) | PRKDCPIK3CBATRATRIPPIK3CA | |
| SCHEMBL807829 | 0.78 | PRKDC (0.38) | PRKDCPIK3CBATRATRIPATM | |
| SCHEMBL10070584 | 0.76 | GRIN2B (0.47) | PRKDCPIK3CBATRATRIPMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | FARS2, TIAL1, DHFR | PRKDC 3135/4885PIK3CB 1750/4885ATR 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.